Latest Pharmaceuticals News

Page 1 of 40
IDT Australia expects FY27 revenue of $19 million to $20 million and EBITDA of $1 million to $1.5 million, marking a projected swing from a $0.92 million FY26 loss. The forecast rests on larger customer contracts, a five-year radiopharmaceutical deal and roughly $7 million of manufacturing upgrades.
Victor Sage
Victor Sage
18 Nov 2026
Xenitra has secured a three-year strategic cooperation agreement with JD Health carrying a non-binding A$100 million sales target across prescription medicines, OTC products, FSMP products and health products. The first order is expected in December, with sales targeted to begin in January 2027, but the agreement does not guarantee revenue or impose a penalty if the target is missed.
Victor Sage
Victor Sage
18 Nov 2026
Viatris has completed its US$1.69 billion cash acquisition of Pacira BioSciences, taking full ownership of the non-opioid pain management company. Pacira is expected to contribute US$90 million to US$100 million in revenue over the remainder of 2026.
Victor Sage
Victor Sage
18 Nov 2026
Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
Victor Sage
Victor Sage
17 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Viatris has lifted its 2026 guidance midpoints across revenue, adjusted EBITDA, adjusted EPS and free cash flow after a resilient third quarter. The upgrade comes alongside a US$1.65 billion Pacira acquisition and a costly manufacturing suspension in India.
Victor Sage
Victor Sage
5 Nov 2026
Amgen delivered 8% third-quarter revenue growth and a 19% increase in GAAP diluted EPS, while newer medicines continued to expand. The result came alongside sharp declines in Prolia and XGEVA sales from biosimilar competition and a busy pipeline of late-stage programmes.
Victor Sage
Victor Sage
4 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.
Victor Sage
Victor Sage
28 Oct 2026
Botanix’s Sofdra prescriptions rose 5.3% in the September quarter, but flat net revenue and a sharp cash decline have forced a major reset. The company is targeting a roughly 50% reduction in operating expenses while assessing licensing, acquisitions and broader strategic transactions.
Victor Sage
Victor Sage
27 Oct 2026
Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.
Victor Sage
Victor Sage
26 Oct 2026
BLS Pharmaceuticals has started FY27 with its strongest quarter on record, reporting A$26.7 million in unaudited revenue and positive operating cash flow. The company reaffirmed its A$105 million to A$115 million revenue guidance while continuing to invest in Australian and Scottish manufacturing capacity.
Victor Sage
Victor Sage
21 Oct 2026

Browse the archive

Full archive